These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 31960518)

  • 21. Expression Profile Analysis of Zinc Transporters (ZIP4, ZIP9, ZIP11, ZnT9) in Gliomas and their Correlation with IDH1 Mutation Status.
    Kang X; Chen R; Zhang J; Li G; Dai PG; Chen C; Wang HJ
    Asian Pac J Cancer Prev; 2015; 16(8):3355-60. PubMed ID: 25921144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncogenic IDH1 Mutations Promote Enhanced Proline Synthesis through PYCR1 to Support the Maintenance of Mitochondrial Redox Homeostasis.
    Hollinshead KER; Munford H; Eales KL; Bardella C; Li C; Escribano-Gonzalez C; Thakker A; Nonnenmacher Y; Kluckova K; Jeeves M; Murren R; Cuozzo F; Ye D; Laurenti G; Zhu W; Hiller K; Hodson DJ; Hua W; Tomlinson IP; Ludwig C; Mao Y; Tennant DA
    Cell Rep; 2018 Mar; 22(12):3107-3114. PubMed ID: 29562167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
    Nesvick CL; Zhang C; Edwards NA; Montgomery BK; Lee M; Yang C; Wang H; Zhu D; Heiss JD; Merrill MJ; Ray-Chaudhury A; Zhuang Z
    J Neurooncol; 2016 Oct; 130(1):111-122. PubMed ID: 27568035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma.
    Esmaeili M; Hamans BC; Navis AC; van Horssen R; Bathen TF; Gribbestad IS; Leenders WP; Heerschap A
    Cancer Res; 2014 Sep; 74(17):4898-907. PubMed ID: 25005896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.
    Ikota H; Nobusawa S; Arai H; Kato Y; Ishizawa K; Hirose T; Yokoo H
    Brain Tumor Pathol; 2015 Oct; 32(4):237-44. PubMed ID: 26006098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
    Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
    Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
    Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
    Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.
    Chaumeil MM; Larson PE; Woods SM; Cai L; Eriksson P; Robinson AE; Lupo JM; Vigneron DB; Nelson SJ; Pieper RO; Phillips JJ; Ronen SM
    Cancer Res; 2014 Aug; 74(16):4247-57. PubMed ID: 24876103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes.
    Kawakami S; Ochiai K; Azakami D; Kato Y; Michishita M; Morimatsu M; Ishiguro-Oonuma T; Onozawa E; Watanabe M; Omi T
    Vet Res Commun; 2018 Mar; 42(1):49-56. PubMed ID: 29285579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
    Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
    PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extracellular glutamate and IDH1
    Tiburcio PDB; Gillespie DL; Jensen RL; Huang LE
    J Neurooncol; 2020 Feb; 146(3):427-437. PubMed ID: 32020473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis.
    Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas.
    Ren F; Zhao Q; Huang L; Zheng Y; Li L; He Q; Zhang C; Li F; Maimela NR; Sun Z; Jia Q; Ping Y; Zhang Z; Chen X; Yue Y; Liu S; Cao L; Zhang Y
    Immunol Cell Biol; 2019 May; 97(5):457-469. PubMed ID: 30575118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas.
    Liubinas SV; D'Abaco GM; Moffat BM; Gonzales M; Feleppa F; Nowell CJ; Gorelik A; Drummond KJ; O'Brien TJ; Kaye AH; Morokoff AP
    Epilepsia; 2014 Sep; 55(9):1438-43. PubMed ID: 24903073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isocitrate Dehydrogenase 1 Expression in Canine Gliomas.
    Fraser AR; Bacci B; le Chevoir MA; Long SN
    J Comp Pathol; 2018 Nov; 165():33-39. PubMed ID: 30502793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas.
    Gargini R; Segura-Collar B; Herránz B; García-Escudero V; Romero-Bravo A; Núñez FJ; García-Pérez D; Gutiérrez-Guamán J; Ayuso-Sacido A; Seoane J; Pérez-Núñez A; Sepúlveda-Sánchez JM; Hernández-Laín A; Castro MG; García-Escudero R; Ávila J; Sánchez-Gómez P
    Sci Transl Med; 2020 Jan; 12(527):. PubMed ID: 31969485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
    Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
    J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
    Sipayya V; Sharma I; Sharma KC; Singh A
    J Cancer Res Ther; 2012; 8(4):598-601. PubMed ID: 23361281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
    Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
    Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.